Back to top
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
A Bio-Techne Corporation (TECH - Free Report) brand, ProteinSimple, recently expanded the Ella immunoassay platform through the launch of a 32x4 Simple Plex cartridge. The cartridge provides more accurate results at a lower cost. Notably, ProteinSimple falls under the Protein Platforms division of Bio-Techne.
Simple Plex immunoassays have the same features as the "gold standard" ELISA and run on the fully-automated Ella platform. The Simple Plex cartridges in combination with the automated Ella platform have helped skip the manual steps and provide more accurate and dynamic 4-5 logs than traditional ELISAs in an hour.
Per management, the combination delivers solutions that enable higher throughput immunoassays.
In the last reported fourth quarter, Bio-Techne witnessed 22% year-over-year revenue growth (up 24% organically) at the Protein Platforms division. Notably, this quarter marked the sixth straight quarter of double-digit organic growth. Per management, growth was driven by new product introduction and applications.
The company is presently focusing on strengthening its position in this segment banking on the solid prospects. According to a report by Markets and Markets, the global immunoassay market is expected to reach a value of $25.45 billion by 2021, at a CAGR of 8.2% from 2016 to 2021. Considering the opportunities, we see the latest development as a strategic one.
However, the company faces tough competition in the industry from well-established players like Thermo Fisher Scientific Inc. (TMO - Free Report) , Luminex Corporation and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>